Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
StockNews.AI · 2 days
High Materiality9/10
Information
, /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused ...
Original sourceAI Summary
Haemonetics Corporation has secured FDA 510(k) clearance for its NexSys PCS Plasma Collection System, incorporating Persona PLUS technology that tailors collections to individual donors. This advancement is expected to improve plasma yields and reduce costs, positioning Haemonetics favorably in a growing market for plasma-derived therapies.
Sentiment Rationale
The FDA clearance is likely to enhance HAE's competitive edge and revenue potential. Historically, FDA approvals have resulted in stock price increases for similar medical technology companies.
Trading Thesis
Consider HAE a buy as FDA approval could enhance market position and revenues in the near term.
Market-Moving
- FDA clearance may significantly boost HAE's market share in plasma collection.
- Improved product efficiency could lead to increased sales and revenue growth.
- Growing demand for plasma therapies supports Haemonetics' innovative solutions.
- Successful commercialization of Persona PLUS may meet operational efficiencies in plasma centers.
Key Facts
- Haemonetics receives FDA 510(k) clearance for NexSys PCS Plasma Collection System.
- The new technology enhances plasma collection tailored to each donor.
- Clinical trials involved over 30,000 donations, showcasing effectiveness.
- Persona PLUS technology improves plasma yield, lowering cost-per-liter.
- Growing demand for plasma therapies intensifies need for innovative solutions.
Companies Mentioned
- Haemonetics Corporation (HAE): Leader in plasma collections; FDA approval bolsters competitive advantage.
Corporate Developments
This news falls under 'Corporate Developments' as it highlights a significant product advancement for Haemonetics. The FDA clearance positions the company to better capitalize on increasing market demands for plasma-derived therapies.